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HER2 inhibitors is required for optimal antitumor
activity in HER2+ breast cancer cells
Brent N Rexer1,2,3,4*, Siprachanh Chanthaphaychith1, Kimberly Brown Dahlman2,4 and Carlos L Arteaga1,2,3,4Abstract
Introduction: Despite multiple advances in the treatment of HER2+ breast cancers, resistance develops even to
combinations of HER2 targeting agents. Inhibition of PI3K pathway signaling is critical for the efficacy of HER2
inhibitors. Activating mutations in PIK3CA can overlap with HER2 amplification and have been shown to confer
resistance to HER2 inhibitors in preclinical studies.
Methods: Lapatinib-resistant cells were profiled for mutations in the PI3K pathway with the SNaPshot assay.
Hotspot PIK3CA mutations were retrovirally transduced into HER2-amplified cells. The impact of PIK3CA mutations on
the effect of HER2 and PI3K inhibitors was assayed by immunoblot, proliferation and apoptosis assays. Uncoupling
of PI3K signaling from HER2 was investigated by ELISA for phosphoproteins in the HER2-PI3K signaling cascade. The
combination of HER2 inhibitors with PI3K inhibition was studied in HER2-amplified xenograft models with wild-type
or mutant PIK3CA.
Results: Here we describe the acquisition of a hotspot PIK3CA mutation in cells selected for resistance to the HER2
tyrosine kinase inhibitor lapatinib. We also show that the gain of function conferred by these PIK3CA mutations
partially uncouples PI3K signaling from the HER2 receptor upstream. Drug resistance conferred by this uncoupling
was overcome by blockade of PI3K with the pan-p110 inhibitor BKM120. In mice bearing HER2-amplified wild-type
PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression. The addition of
a PI3K inhibitor further improved tumor regression and decreased tumor relapse after discontinuation of treatment.
In a PIK3CA-mutant HER2+ xenograft, PI3K inhibition with BKM120 in combination with lapatinib and trastuzumab
was required to achieve tumor regression.
Conclusion: These results suggest that the combination of PI3K inhibition with dual HER2 blockade is necessary to
circumvent the resistance to HER2 inhibitors conferred by PIK3CA mutation and also provides benefit to HER2+
tumors with wild-type PIK3CA tumors.Introduction
Amplification of the HER2 oncogene occurs in approxi-
mately 25% of human breast cancers and predicts
response to therapies targeting human epidermal growth
factor receptor 2 (HER2), including trastuzumab, a
monoclonal antibody directed against HER2, and lapati-
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stated.epidermal growth factor receptor (EGFR) [1,2]. HER2 is
a member of the ErbB family of receptor tyrosine ki-
nases (RTKs), which form both homo- and heterodi-
mers, resulting in the activation of downstream signaling
pathways [3]. In HER2-amplified cancers, the heterodi-
mer of HER2 with kinase-deficient HER3 is a major acti-
vator of phosphoinositide 3-kinase (PI3K)-Akt signaling,
and HER3, when phosphorylated, can directly couple to
the p85 subunit of PI3K [4]. HER2-amplified tumors
show significant reliance on PI3K-Akt signaling [5,6].
Importantly, inhibition of PI3K-Akt signaling is believed
to be an essential component of the antitumor effect of
HER2-directed therapies [7-9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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human cancers, and among the most frequent alter-
ations are mutations in phosphoinositide 3-kinase cata-
lytic subunit α (PIK3CA), the gene encoding the p110α
catalytic subunit of PI3K. These mutations cluster in
hotspot regions in the helical and kinase domains
of p110α [10,11] and confer a gain of function [12].
PIK3CA hotspot mutations are found in approximately
25% of breast cancers and can overlap with HER2 ampli-
fication [10,13,14]. The presence of these mutations in
HER2-amplified cancer cells confers resistance to trastu-
zumab or lapatinib [7,15-17]. Moreover, aberrant activa-
tion of PI3K-Akt signaling by a PIK3CA mutation
and/or phosphatase and tensin homologue (PTEN) loss
is associated with resistance to trastuzumab in patients
in some studies [15,18,19].
Recent clinical studies have suggested that targeting
HER2-PI3K signaling with combinations of agents that
inhibit HER2 by different mechanisms is more effective
than a single HER2 inhibitor; combining trastuzumab
and lapatinib was more effective than trastuzumab alone
in both the metastatic and neoadjuvant settings [20,21];
and combining two HER2 antibodies, trastuzumab and
pertuzumab, prolonged survival longer than trastuzumab
alone [22]. Preclinical studies have suggested that the
HER2/HER3 signaling complex has sufficient buffering
capacity to withstand incomplete inhibition of HER2
catalytic activity, even in combination with a PI3K in-
hibitor, though this capacity can be overcome by fully in-
activating HER2 catalytic activity with elevated doses of
a TKI that may not be tolerated in clinical practice [23].
Moreover, even so-called dual-targeting of HER2 may
not be sufficient to overcome resistance to HER2 inhib-
ition, particularly in the case of HER2-amplified cancer
with a PIK3CA mutation [16,24]. We have previously
shown that, once resistance to HER2 inhibitors is estab-
lished, inhibition of PI3K added to continued HER2 in-
hibition can overcome resistance [25].
In this work, we show that PIK3CA-activating muta-
tions can be acquired during the development of resist-
ance to HER2 inhibitors and that the presence of these
mutations uncouples PI3K signaling from HER2. We
further demonstrate that adding a PI3K inhibitor to
dual-targeting of HER2 is more effective than HER2 tar-
geting alone in a PI3K wild-type tumor and that the
combination of HER2 and PI3K targeting is required for
tumor regression in a model with HER2 amplification
and PIK3CA mutation.
Methods
Cell cultures, inhibitor treatments and proliferation and
apoptosis assays
BT474, SKBR3, MDA-MB-361, HCC1954 and UACC893
cells were obtained from the American Type CultureCollection (Manassas, VA, USA). SUM190 cells were
purchased from Asterand (Detroit, MI, USA). Lapatinib-
resistant (LR) cell lines were generated as described
previously [25] and cultured in the presence of 1 to
2 μM lapatinib. Lapatinib ditosylate and BIBW2992
were obtained from LC Laboratories (Woburn, MA,
USA). BKM120 was obtained from Selleck Chemicals
(Houston, TX, USA). Trastuzumab and pertuzumab
were obtained from the Vanderbilt University Medical
Center outpatient pharmacy. Unless otherwise noted,
cells were treated with inhibitors at the following con-
centrations: lapatinib, 1 μM; trastuzumab, 10 μg/ml;
BKM120, 1 μM; and BIBW2992, 1 μM. Cell proliferation
was measured using the sulforhodamine B (SRB) re-
agent. Cells plated in 96-well plates were treated with in-
hibitors and fixed in 1% trichloroacetic acid after 72-
hour treatment. Plates were rinsed with water and air-
dried, then stained with 0.4% SRB in 1% acetic acid. Ex-
cess stain was removed by washing with 1% acetic acid,
and plates were air-dried. Stained cells were solubilized
in 10 mM Tris–HCl, pH 7.4, and absorbance at 590 nm
was measured in a plate reader. Apoptosis was measured
at 24 hours using the Caspase-Glo reagent (Promega,
Madison, WI, USA) according to the manufacturer’s in-
structions. For longer-term growth assays, cells were
seeded into six-well plates and treated with inhibitors as
indicated. Media and inhibitors were replenished twice
weekly, and cells were grown for 2 to 3 weeks until conflu-
ence in the untreated wells. Cells were fixed and stained in
20% methanol with 0.5% crystal violet and washed with
water. Dried plates were imaged on a flatbed scanner.
Generation of PIK3CA mutant cells
BT474 and SKBR3 parental cells were transduced with
an amphotrophic retrovirus (LZRS) with neomycin re-
sistance produced by Phoenix-AMPHO packaging cells
containing C-terminal hemagglutinin (HA)-tagged bo-
vine wild-type PIK3CA or E545K or H1047R mutations
cloned from the JP1520 retroviral vector, as described
previously [26]. To generate LR cell lines, transduced
cells were treated with 1 μM lapatinib for approximately
4 to 6 weeks. Wild-type PIK3CA-expressing cells did not
survive selection. Mutant-expressing, lapatinib-selected
cells were maintained in the presence of 1 μM lapatinib.
SNaPshot genotyping and Sanger sequencing
Genomic DNA was isolated from parental and LR BT474
cells and analyzed by the SNaPshot mutational profiling
method (SNaPshot; Vanderbilt, NY, USA). This assay in-
volves multiplexed polymerase chain reaction (PCR) and
multiplexed single-base primer extension, followed by ca-
pillary electrophoresis [27-29]; Vandana G Abramson et al.,
unpublished data. The current assay was designed to detect
18 somatic point mutations in three genes (Additional file 1:
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target DNA, and PCR was performed using the following
conditions: 95°C (8 minutes), followed by 40 cycles at (95°C
(20 seconds), 58°C (30 seconds) and 72°C (1 minute)) and
then a final extension at 72°C (3 minutes) (Additional file 2:
Table S2). Next, PAGE-purified primers were pooled to-
gether, and multiplex single-base extension reactions were
performed on ExoSAP-IT-treated (USB/Affymetrix, Santa
Clara, CA, USA) PCR products using the following condi-
tions: 96°C (30 seconds), followed by 35 cycles at (96°C
(10 seconds), 50°C (5 seconds) and 60°C (30 seconds))
(Additional file 3: Table S3). Extension products were ap-
plied to capillary electrophoresis in an ABI 3730 DNA
Analyzer (Applied Biosystems, Foster City, CA, USA), and
the data were interpreted using ABI GeneMapper software
(version 4.0; Applied Biosystems). Human male genomic
DNA (Promega) was used as a wild-type control. Spiking
primers were mixed to create a pan-positive control mix
for the assay (Additional file 4: Table S4).
To validate the SNaPshot result, exon 9 of PIK3CA was
amplified by high-fidelity PCR from genomic DNA and
sequenced by traditional Sanger sequencing methods.
The primer sequences are as follows: 5′-TTCAGCAGT
GTGGTAAAGTTC-3′ forward; 5′GAGGCCAATCTTT
TACCAAGC-3′ reverse.
Immunoblot analysis and p85 immunoprecipitation
Cells were treated with inhibitors for 3 hours, and
lysates were prepared as described previously [25].
Lysates were resolved on 7.5% acrylamide gels and
transferred to Immobilon-FL PVDF (EMD Millipore,
Billerica, MA, USA) and incubated in primary antibodies
overnight at 4°C. Blots were washed and incubated with
infrared fluorescent dye secondary antibody conjugates
(LI-COR Biosciences, Lincoln, NE, USA), and blots were
imaged using a LI-COR Odyssey scanner. Antibodies
from the following sources were used for analysis:
pHER2 Y1248 (R&D Systems, Minneapolis, MN, USA);
Y877 pHER2 (Epitomics, Burlingame, CA, USA); Y1221/
2 pHER2, Y11197 and Y1289 pHER3, S473 pAkt, Akt,
S240/44 pS6, pErk1/2, Erk, and p110α PI3K (Cell Signal-
ing Technology, Danvers, MA, USA); p85 N-terminal
Src homology 2 (SH2) domain (EMD Millipore); HA
(Covance, Princeton, NJ, USA); actin (Sigma-Aldrich, St
Louis, MO, USA); HER2 (Thermo Fisher, Pittsburgh,
PA, USA); and glyceraldehyde 3-phosphate dehydrogen-
ase (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
To analyze p110α isoforms bound to p85, lysates were
prepared from wild-type or mutant-expressing cells and
incubated with p85 rabbit antibody (directed against the
N-terminal SH2 domain) overnight at 4°C as described
previously [30]. Antibody complexes were isolated
with Dynabeads Protein A (Life Technologies) and
washed. Beads were boiled in SDS sample buffer andresolved on polyacrylamide gels, then immunoblotted
with HA, p110α and p85 antibodies. Bands were
quantitated using the LI-COR Odyssey scanner and
Image Studio software. Mean values from triplicate
experiments were compared by analysis of variance
(ANOVA).Phosphoprotein ELISA analysis
PathScan Sandwich ELISA kits for pHER2, pAkt and
pS6 were purchased from Cell Signaling Technology and
used according to the manufacturer’s instructions. Ly-
sates from cells treated with a range of lapatinib doses
for 4 hours were prepared, and protein concentration
determined by bicinchoninic acid assay (Pierce Biotech-
nology, Rockford, IL, USA). Lysates were diluted and in-
cubated in enzyme-linked immunosorbent assay (ELISA)
plates overnight at 4°C, then washed and developed
according to the protocol. Absorbance values were read
on a BioTek Epoch microplate optical reader (BioTek,
Winooski, VT, USA) and normalized for each experi-
ment to values for untreated cells. ELISA experiments
were repeated in triplicate. Mean values ± SEM from the
three experiments were used to plot log(inhibitor) vs.
response curves using a variable slope model and to
determine half-maximal inhibitory concentrations (IC50)
using GraphPad Prism software (GraphPad Software, La
Jolla, CA, USA). For statistical analysis, IC50 values for
each phosphoprotein were compared between wild-type
and mutant cells by ANOVA.Xenograft experiments
Animal studies were approved by the Vanderbilt University
Medical Center Institutional Animal Care and Use Com-
mittee. BT-474 or HCC1954 cells (approximately 5 × 106 in
50% Matrigel) were injected into female athymic nude
mice. For BT474 cells, mice were implanted with 60-day,
0.72-mg, slow-release estrogen pellets (Innovative Research
of America, Sarasota, FL, USA) on the day prior to injec-
tion. After tumors reached ≥250 mm3, mice were randomly
assigned to treatment with trastuzumab (30 mg/kg by intra-
peritoneal injection twice weekly), lapatinib (100 mg/kg by
oral gavage daily) and/or BKM120 (30 mg/kg by oral gavage
daily). Tumors were measured with calipersn and tumor
volume in cubic millimeters was calculated by the formula
length/(2 ×width2). Mean tumor volumes for each treat-
ment group are displayed on log2 scale. Kaplan-Meier
curves were constructed using the time point at which
tumor volumes exceeded 100 mm3.
Results
Acquired PIK3CA mutation in lapatinib-resistant cells
We previously showed that LR cells exhibit continued
activation of PI3K signaling despite inhibition of the
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ciated with maintenance of PI3K signaling in these drug-
resistant cells, we profiled them using the SNaPshot
assay [27–29; Vandana G Abramson et al., unpublished]
for a panel of mutations in PIK3CA, AKT and PTEN
(Additional file 1: Table S1). Four of the six LR cell lines
were derived from cells with preexisting hotspot PIK3CA
mutations. None of the resistant cell lines acquired AKT
or PTEN mutations. However, BT-474 LR cells acquired
an E542K PIK3CA mutation (Figure 1A). We confirmed
the presence of this mutation in cDNA by Sanger se-
quencing. Parental cells did not have any detectable
E542K mutant sequence. The mutation persisted in LR
cells even after culture in the absence of lapatinib for
more than 2 weeks (Figure 1B). The E542 mutation is

















Figure 1 BT474 lapatinib-resistant cells acquire E542K PIK3CA mutatio
lapatinib-resistant (LR) cells reveals a distinct peak corresponding to a G162
9 of PIK3CA confirms the presence of the G1624A nucleotide change in LR
doses of lapatinib, ranging from 0.001 to 10 μM, were analyzed by immunoknown to contain PIK3CA mutations have either an
E545K or H1047R mutation [10,14].
PIK3CA mutation partially uncouples HER2 inhibition for
phosphoinositide 3-kinase signaling
We observed that the four HER2-amplified cell lines that
contain de novo PIK3CA mutations develop resistance to
lapatinib more rapidly than PIK3CA wild-type cells in
chronic cell culture. Thus, because the BT474 cells ac-
quired a PIK3CA mutation upon the development of
lapatinib resistance, we reasoned that the gain of func-
tion conferred by this mutation in p110α uncouples
downstream PI3K signaling from HER2 and thereby
blunts the inhibitory effect of lapatinib. We first evalu-
ated response to lapatinib in parental and LR BT474
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n. (A) SNaPshot analysis of genomic DNA isolated from parental and
4A nucleotide change in resistant cells. (B) Sanger sequencing of exon
cells. (C) Lysates from parental and LR cells treated with increasing
blotting with the indicated antibodies.
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Figure 2 PIK3CA mutation uncouples phosphoinositide 3-kinase signaling from HER2 inhibition by lapatinib. (A) BT474 and SKBR3
cells infected with wild-type, E545K or H1047R constructs were treated with lapatinib at the indicated doses, and lysates were analyzed by
immunoblotting with the indicated antibodies. (B) Lysates from PIK3CA wild-type or mutant expressing cells treated with a range of lapatinib
doses (0.0016 to 5 μM) were analyzed by ELISA for pHER2, pAkt and pS6. Half-maximal concentration (IC50) values were calculated, and the mean
log IC50 ± SEM values for three replicate dose–inhibitor curves are shown. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. (C) HER2+ cell lines
with wild-type PIK3CA (BT474 or SKBR3) or with a PIK3CA mutation (MDA361, HCC1954, SUM190 or UACC893) were treated with varying lapatinib
doses and analyzed as described in (B). Mean log IC50 values from three replicates ± SEM are shown. Mean IC50 data are shown in Table 1.
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phosphorylation was observed. After treatment of cells
with increasing doses of lapatinib, we observed a similar
inhibition of HER2 phosphorylation in parental and re-
sistant cells, but the resistant cells with an acquired
E542K mutation showed only very limited inhibition of
PI3K signaling as measured by Akt and S6 phosphoryl-
ation (Figure 1C).
We next transduced parental BT474 and SKBR3 cells
with wild-type, E545K or H1047R PIK3CA retroviral
constructs. Expression of the ectopic p110α construct
was verified by Western blot analysis for a C-terminal
HA-tag (Additional file 5: Figure S1). We then evaluated
the inhibition of pHER2 and PI3K signaling with a range
of lapatinib doses. Similarly to BT474 LR cells with
acquired E542K mutation, cells with the other hotspot
mutations showed a blunted inhibitor response of PI3K
signaling to lapatinib with persistent PI3K-Akt signaling
(Figure 2A).
To better quantify the signaling output of mutant
PIK3CA in cells in which HER2 was inhibited, we mea-
sured pHER2 by ELISA in cells treated with lapatinib
and compared the IC50 for HER2 inhibition to the IC50
for PI3K inhibition as measured by Akt S473 and S6
S240/244 phosphorylation. We first compared BT474
and SKBR3 cells (without endogenous hotspot muta-
tions) infected with wild-type, E545K or H1047R p110α
retroviral constructs. As expected, IC50 data for inhib-
ition of HER2 by lapatinib were similar between wild-
type and PIK3CA mutant expressing cells (Figure 2B).
However, both cell lines expressing either mutant




BT474 LR 0.0204 0.3925
BT474 wt 0.0798 0.0387
BT474 E545K 0.0852 0.1098
BT474 H1047R 0.0978 0.1336
SKBR3 0.0254 0.0077
SKBR3 wt 0.0297 0.0293
SKBR3 E545K 0.0211 0.0936





aWT, Wild type. Half-maximal inhibitory concentration (IC50) values for inhibition of
enzyme-linked immunosorbent assay (dose–response curves are shown in Addition
Mean IC50 values derived from at least three separate experiments are shown. For p
with PIK3CA mutations were compared to average values for cells without hotspotIC50 for both Akt and S6 phosphorylation (Figure 2B
and Additional file 6: Figure S2). For cells expressing
ectopic mutant PI3K, the increase in IC50 was typic-
ally two- to threefold higher for the mutant cells than
for the wild-type cells (Table 1). Interestingly, we ob-
served a similar increase in the IC50 for pAkt and
pS6 in the LR BT474 cells with an acquired E542K
mutation (Additional file 7: Figure S3). These data
suggest that mutant p110α uncouples PI3K signaling
from HER2.
We next tested whether a similar partial uncoupling
of PI3K signaling from HER2 activation was occurring
in cells with endogenous PI3K hotspot mutations. We
measured the IC50 values for HER2 and PI3K inhib-
ition in four cell lines with endogenous PIK3CA
mutations and compared them to the data for BT474
and SKBR3 cells. Again, we observed similar magni-
tudes of inhibition of HER2, but cell lines with
endogenous PI3K mutations, particularly H1047R,
showed an increased IC50 for pAkt and, in one cell
line, for pS6 (Figure 2C and Additional file 8: Figure
S4). There was a trend toward increased IC50 for in-
hibition of S6 phosphorylation by lapatinib, but the
difference was not statistically significant. We ob-
served in the dose–response curves that the level of
the remaining S6 phosphorylation, even at maximal
(5 μM) doses of lapatinib, was higher than that of
wild-type cells (Additional file 8: Figure S4). This
finding confirms that cell lines with endogenous PI3K
mutations have a blunted inhibitory response and ex-
plains in part how resistance to lapatinib may emerge
more quickly in PIK3CA mutant cells.tinib inhibition of HER2 and signaling proteins in PIK3CA














HER2, Akt and S6 phosphorylation by lapatinib treatment were determined by
al file 6: Figure S2, Additional file 7: Figure S3 and Additional file 8: Figure S4).
hosphoinositide 3-kinase signaling proteins Akt and S6, IC50 values from cells
mutations (BT474 and SKBR3).
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mutant PIK3CA
We reasoned that cells that developed resistance to lapa-
tinib by exploiting the uncoupling of PI3K from HER2
inhibition to allow escape from that inhibition would
rely on the gain of function conferred by the mutant
p110α isoform to allow for continued signaling in the
presence of lapatinib. Thus, after selection for resistance,
we hypothesized that the pool of p110α in complex with
p85 and available for PI3K signaling would contain more
mutant p110α than that available before selection for re-
sistance. To test this hypothesis, BT474 and SKBR3 cells
expressing ectopic HA-tagged E545K or H1047R p110α
were selected for lapatinib resistance for 4 to 6 weeks.
After an initial period of slower growth, the lapatinib-
selected cells proliferated. We observed continued inhib-
ition of HER2 by lapatinib, but recovery of Akt and S6
phosphorylation (Figure 3A). In LR cells, PI3K-Akt sig-
naling was still dependent on p110α catalytic activity, as
treatment with the PI3K inhibitor BKM120 abolished
S473 Akt phosphorylation in both parental and LR ec-
topic PIK3CA mutant–expressing cells (Figure 3B).
We hypothesized that the gain of function conferred
by the mutant p110α isoform in the LR cells would re-
sult in the preferential engagement of the mutant iso-
form for PI3K signaling under the selective pressure
of HER2 inhibition. As an indirect measure of this
utilization of mutant PI3K, we tested whether the PI3K
signaling complex in the LR cells would be enriched for
the mutant p110α isoform. We immunoprecipitated the
pool of p110α in a complex with p85 using a p85 anti-
body and evaluated the level of mutant isoform present
before and after lapatinib selection by immunoblotting
for the HA-tag. In BT474 cells, we observed that more
of the H1047R mutant p110α was detected in a complex
with p85 in resistant cells than in parental cells
(Figures 3C and 3D). We found a similar increase in HA
expression in p85 immunoprecipitates from SKBR3 cells
expressing H1047R p110α, but this increase did not per-
sist after normalizing for levels of immunoprecipitated
p85 (Figure 3D and Additional file 9: Figure S5). We did
not observe any increase in levels of the E545K mutant
in a complex with p85 in either cell line. The E545K mu-
tation has been proposed to alter interaction with p85
and so may have a different mechanism of action than
the H1047R catalytic site mutation [12,31]. This may ex-
plain why levels of E545K mutant p110α did not in-
crease in PI3K from LR cells.
HER2 inhibitor resistance conferred by phosphoinositide
3-kinase mutation is susceptible to p110α inhibition
The data we compiled in this study suggest that the gain
of function conferred by PIK3CA mutations partially
uncouples PI3K signaling from HER2 and allows foreventual escape from HER2 inhibition, but that signaling
remains susceptible to inhibitors of p110α. This idea is
in agreement with previous reports that lapatinib resist-
ance from PI3K mutations or PTEN loss could be
overcome by combining lapatinib with a dual PI3K/
mammalian target of rapamycin (PI3K/mTOR) inhibitor
[16]. Another possibility is that the gain of function of
mutant PI3K can amplify low levels of HER2 signaling
that remain after single-inhibitor treatment of HER2+
breast cancer [23], but the combination of dual HER2
inhibitor blockade may reduce this low level of signaling
and thus inhibit even PIK3CA mutant cancers. This idea
is consistent with recent clinical data indicating that the
combination of trastuzumab and lapatinib or trastuzu-
mab and pertuzumab is more effective than single HER2
inhibitor therapy [20-22]. To test whether additional
HER2 blockade could overcome resistance to single-
agent lapatinib or trastuzumab conferred by PI3K muta-
tion, we treated LR PIK3CA mutant cells with lapatinib
and trastuzumab and with or without the PI3K inhibitor
BKM120. We found that the addition of trastuzumab
did not inhibit the already low level of HER2 phosphor-
ylation or further diminish the minimally detectable
HER3 phosphorylation in these cells, nor did it further
decrease PI3K-Akt signaling through Akt or S6 phos-
phorylation (Figure 4A). This low level of signaling ap-
pears to be sufficient for cell proliferation, as ectopic
PI3K expression allowed for continued proliferation of
cells in the presence of both trastuzumab and lapatinib
(Additional file 10: Figure S6). Only the addition of the
PI3K inhibitor resulted in PI3K pathway inhibition
(Figure 4A). We also tested the addition of pertuzumab,
a monoclonal antibody against HER2 that recognizes a
different epitope than trastuzumab, and BIBW2992, a co-
valent inhibitor of EGFR/HER2 RTKs. None of these add-
itional HER2 inhibitors resulted in any decrease in cell
proliferation or increase in apoptosis in LR cells; only the
addition of PI3K inhibition resulted in decreased prolifera-
tion and the induction of apoptosis (Figures 4B and 4C).
HER2 inhibitors in combination with phosphoinositide
3-kinase inhibitors can prevent outgrowth of
resistant tumors
Because we did not find any benefit associated with add-
itional HER2 inhibitors once resistance to an HER2 in-
hibitor was established in cell culture, we sought to test
whether addition of a PI3K inhibitor to the combination
of lapatinib and trastuzumab would prevent the out-
growth of resistant tumors, both with and without PI3K
mutations. We first used BT474 cells (without PI3K
hotspot mutations). As previously reported [32], trastu-
zumab and lapatinib together induced BT474 tumor re-
gression. Treatment with BKM120 alone was able to
block tumor growth, but did not induce any tumor
E545K H1047R
Pre LR Pre LR
- + - + + + - + - + + +
- - + + - + - - + + - +
E545K H1047R
Pre LR Pre LR
- + - + + + - + - + + +
- - + + - + - - + + - +
WT E545K H1047R
Pre LR Pre LR
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Figure 3 Lapatinib-resistant PIK3CA mutant cell lines show reactivation of phosphoinositide 3-kinase and utilize mutant p110α for
phosphoinositide 3-kinase signaling. (A) Cells expressing E545K or H1047R were selected for lapatinib resistance. Unselected cells (Pre) were
treated with lapatinib for 3 hours and analyzed along with lapatinib-resistant (LR) cells in the presence of lapatinib by immunoblotting with the
indicated antibodies. (B) Lapatinib-sensitive and LR cells were treated with lapatinib and/or BKM120 for 3 hours, and lysates were analyzed by
immunoblotting. (C) Phosphoinositide 3-kinase (PI3K) was immunoprecipitated from PIK3CA mutant–expressing cells before and after selection
for lapatinib resistance with a p85 antibody. Complexes were separated by SDS-PAGE, and expression of mutant p110α was determined by
immunoblot analysis for the hemagglutinin (HA)-tag. (D) HA band intensity detected by infrared fluorescence was quantified using a LI-COR
Odyssey imaging system. Mean HA intensity normalized to p85 intensity from at least four replicate experiments is shown (bars = SEM).
Rexer et al. Breast Cancer Research 2014, 16:R9 Page 8 of 14
http://breast-cancer-research.com/content/16/1/R9regression. Combination of a single inhibitor of HER2
with a PI3K inhibitor appeared to be somewhat effective
at inducing tumor regression, with a magnitude of bene-
fit similar to the trastuzumab/lapatinib combination.
Only the combination of all three drugs was sufficient to
induce a robust regression in tumor growth, however,
such that all of the mice in the treatment group showedcomplete regression of tumor growth after about 3 weeks
of treatment (Figure 5B). At the end of 4 weeks of treat-
ment, only residual tumors in the BKM120-only or
dual-therapy groups were available for analysis, and
we observed blockade of PI3K-Akt signaling by the
PI3K inhibitor in these residual tumors (Additional

















+ + + +
- + - +






+ + + +
- + - +
- - + +
HCC1954 LR
(H1047R)
+ + + +
- + - +
- - + +
UACC893 LR
(H1047R)
+ + + +
- + - +
- - + +
Figure 4 Blockade of phosphoinositide 3-kinase, but not additional HER2 blockade, inhibits phosphoinositide 3-kinase signaling in
lapatinib-resistant cells with PIK3CA mutation. (A) Lapatinib-resistant cells in the presence of lapatinib were treated with trastuzumab
overnight, with BKM120 or with the combinations as indicated, and lysates were analyzed by immunoblotting. (B) LR cell lines were plated in
96-well plates. Twenty-four hours after plating, cells were treated with inhibitors as indicated and fixed after seventy-two hours of treatment
(lap = lapatinib, tras = trastuzumab, pert = pertuzumab and BKM = BKM120). Cells were stained with sulforhodamine B (SRB). Mean SRB absorbance
normalized to cells treated with lapatinib only is shown (duplicates from two separate experiments; bars = SEM). (C) Cells were treated as
described in (B), and apoptosis was measured by luminescence after 24-hour treatment with the Caspase-Glo reagent. Mean luminescence
(duplicates from two experiments) normalized to lapatinib only is displayed (bars = SEM).
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sion than two-drug combinations, there were some
mice in each group with complete tumor regression
with dual- or triple-therapy. To determine whether
the response to all three drugs was more durable
than two-drug combinations, we followed mice after
28 days of treatment for tumor regrowth. Tumors
recurred more rapidly in the trastuzumab/lapatinib
combination–treated group, although all groups had
at least one mouse with recurrent tumor growth. In
all cases where significant recurrence was observed,
retreatment with the combination of all three drugs
appeared to be effective (black arrows in Figure 5C).
We next tested the combination of HER2 and PI3K in-
hibition in a xenograft model of HCC1954 cells with en-
dogenous an H1047R PIK3CA mutation. These tumorsshowed continued growth in the presence of trastuzu-
mab or lapatinib as single agents, further suggesting that
PIK3CA mutations confer resistance to HER2 inhibitors
(Figure 5D). In these tumors, the combination of trastu-
zumab and lapatinib was unable to induce tumor regres-
sion as it did in BT474 xenografts. BKM120 alone was
as effective at inhibiting growth as dual HER2 inhibition,
but the combination of HER2 and PI3K inhibitors was
required to induce tumor regression. Unlike treatment
of HER2+/PIK3CA wild-type tumors, no complete re-
gressions were observed in any treatment group, though
most tumors in the triple-therapy group remained only
barely palpable at the end of treatment. After 28 days,
treatment was stopped and mice were again followed for
tumor recurrence, which eventually developed in about





Figure 5 (See legend on next page.)
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Figure 5 Phosphoinositide 3-kinase inhibition combined with HER2 inhibition is more effective at inducing tumor regression than
HER2 inhibition alone. (A) Mice were injected with BT474 cells, and, after tumor formation, mice were treated with trastuzumab (T), lapatinib (L)
or BKM120 (B) in the combinations indicated. Tumor growth was measured twice weekly. The log2 tumor volume data is shown over the 28-day
treatment course (bars = SEM). (B) Kaplan-Meier plot showing the number of mice in each treatment group whose tumors regressed to below
100 mm3 in volume during treatment. The number of responses and the total number in each group are displayed above the curve. (C) After
28 days of treatment, mice whose tumors had regressed were followed for recurrence. Tumor volume for individual mice is plotted with the color
according to the initial treatment group. Arrows indicate retreatment with T + L + B. (D) Mice were injected with HCC1954 cells (H1047R PIK3CA
mutant), and, after tumor formation, mice were treated with trastuzumab (T), lapatinib (L) or BKM120 (B) alone or in the combinations indicated.
Tumor growth was measured twice weekly. The log2 tumor volume data are shown over the 28-day treatment course (bars = SEM). Control, T
and L alone mice were killed at day 21 of treatment because of excessive tumor volume. (E) After 28 days of treatment, mice from the T + L + B
group whose tumors had regressed were followed for recurrence. Tumor volumes for individual mice are plotted. Red indicates mice whose
tumors regrew, and those retreated with T + L + B are indicated by the arrow.
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http://breast-cancer-research.com/content/16/1/R9inhibitors was able to reinduce tumor regression, suggest-
ing that tumors remain sensitive to the combination of all
three drugs. These results imply that a longer duration of
treatment would be necessary to induce complete regres-
sion in tumors with the PIK3CA mutation.
Discussion
The importance of the PI3K–Akt axis in oncogenic sig-
naling is becoming increasingly apparent, especially in
the case of HER2+ breast cancer, where inhibition of
PI3K signaling is critical for the antitumor action of
HER2 inhibitors and activating mutations in the PI3K
pathway can confer resistance to HER2 inhibitors. We
show in our present study that acquisition of a hotspot
PIK3CA mutation is a mechanism of acquired resistance
to lapatinib and that PIK3CA mutations partially un-
couple PI3K from HER2 to allow for the development
and maintenance of resistance. Further, targeting of
PI3K itself, in combination with maximal HER2 block-
ade with both an antibody and a TKI, is more effective
than HER2 targeting alone for HER2 tumors without
PIK3CA mutations and is required for HER2 tumors
with PIK3CA mutations.
We and others have found that both helical and cata-
lytic domain mutations of PIK3CA can confer resistance
to HER2 inhibitors [7,16,24,33]. In our biochemical as-
says, ectopic expression of either mutation appeared to
uncouple HER2 inhibition from PI3K signaling to a
similar degree (Figure 2), and cells expressing either mu-
tation showed reactivation of PI3K upon the develop-
ment of resistance [25]. When we assayed resistant cells
for the proportion of mutant vs. wild-type p110α in the
PI3K signaling complex compared to sensitive cells,
however, we observed an increase in utilization of the
H1047R mutant isoform but not the E545K isoform. We
also did not observe the same degree of uncoupling of
downstream signaling in a cell line with endogenous
E545K compared with H1047R expressing cell lines
(Figure 2). This is consistent with different proposed
mechanisms for these mutations, whereby the helical
domain mutant may function primarily to abolish thenormal regulatory inhibition of PI3K, whereas the in-
creased catalytic activity conferred by the kinase domain
mutation may be required by the mutant cells still under
the selective pressure of HER2 inhibition [12,31]. In
either case, catalytic inhibition of p110α was effective at
blocking downstream signaling for both mutations.
This catalytic inhibition of p110α is emerging as an at-
tractive possible therapeutic option, with a number of
inhibitors currently in preclinical and clinical develop-
ment [34]. Several studies have investigated the potential
importance of PI3K inhibition as a therapeutic strategy
in HER2-amplified breast cancer, but these studies have
uncovered feedback loops and other factors that may
limit the use of PI3K inhibitors as single agents. A p110-
specific inhibitor, GDC-0941, inhibited the growth of
HER2-amplified cells in culture, but the combination of
GDC-0941 with trastuzumab was required for tumor
growth inhibition in mice [7]. Interestingly, the combin-
ation of GDC-0941 with antibody inhibitors of HER2
(trastuzumab and pertuzumab) appeared to be more ef-
fective than GDC-0941 in combination with a TKI [35].
In HER2+ cells with PIK3CA mutations, low doses of
lapatinib are ineffective, but the cells are susceptible to
dual PI3K/mTOR inhibitors such as BEZ235 [16] or
INK-128 [36]. In the latter study, however, combination
of the HER2 TKI with the PI3K inhibitor was not able to
induce tumor regression, whereas combination of a
PI3K p110 inhibitor (BKM120) with trastuzumab did re-
sult in tumor regression, albeit in a wild-type PIK3CA
model. In a transgenic HER2+/PIK3CA H1047R mutant
mouse model, tumors that were resistant to the combi-
nations of trastuzumab and lapatinib or trastuzumab
and pertuzumab could be inhibited by BKM120 alone or
in combination with HER2 inhibitors [24]. Those obser-
vations are in agreement with our present findings that
BKM120 alone did not induce tumor regression, but did
result in tumor regression when combined with HER2
inhibitors. This increased efficacy of HER2 and PI3K
inhibitor combinations may be partly explained by
increased Erk signaling and feedback upregulation of
HER3 after PI3K inhibitor treatment alone, whereas
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overcome these compensatory mechanisms [37,38].
Our results support the clinical testing of combina-
tions of PI3K inhibition with maximal HER2 inhibition
for HER2+ breast cancer. In biomarker studies from the
recent CLEOPATRA clinical trial, although the combin-
ation of trastuzumab and pertuzumab was superior to
trastuzumab alone, regardless of PIK3CA mutation sta-
tus, the magnitude of benefit was less for those tumors
with PIK3CA mutations than for wild-type tumors [39].
There is a potential for overlapping toxicities when com-
bining multiple inhibitors, so important questions re-
garding selection of patients and the sequence and
timing of combination therapies remain to be addressed.
Our data suggest that PIK3CA mutation can be acquired
during HER2 inhibitor treatment and that the presence
of a PIK3CA mutation requires PI3K blockade in
addition to HER2 blockade. Despite several lines of pre-
clinical evidence that either PIK3CA mutation can con-
fer HER2 inhibitor resistance, a robust correlation of the
occurrence of PIK3CA mutations with outcomes after
trastuzumab or lapatinib therapy in patients is still lack-
ing. A recent study of PTEN expression and PIK3CA
mutation in HER2+ patients with either recurrent dis-
ease after trastuzumab treatment or progression of
metastatic disease while on trastuzumab therapy showed
a significantly increased frequency of either PTEN loss
or PIK3CA mutation compared to untreated HER2+ tu-
mors, but PIK3CA mutation status alone did not appear
to be significantly enriched in the clinically trastuzu-
mab-refractory cohort [19]. In addition to determining
whether PIK3CA mutation predicts for the eventual de-
velopment of resistance, there is a critical need to under-
stand how frequently PIK3CA mutations occur after
patients develop resistance to HER2 inhibitor treatment.
Another important question is whether these combina-
tions need to be given together as part of the initial
treatment or whether direct PI3K inhibition can be
added after therapeutic resistance develops. In all of our
models of resistance, we found reactivation of PI3K sig-
naling and susceptibility to PI3K inhibition. We also
found that additional HER2 blockade after the develop-
ment of lapatinib resistance was ineffective and that
PI3K inhibition was essential to overcoming resistance.
This suggests that a potentially better-tolerated sequen-
tial approach might be effective, and, indeed, sequential
additive treatment with HER2 inhibitors appears to have
some clinical efficacy, though these patients eventually
develop resistance to combined HER2 blockade [21]. In
our xenograft models, however, we found that up-front
combination of both HER2 and PI3K blockade was most
effective at inducing regression and preventing tumor
regrowth, regardless of PI3K mutation status. In the case
of PIK3CA mutation, this combination was required toinduce tumor regression. This suggests that the combin-
ation of HER2 and PI3K therapies up front, if tolerable,
might provide optimal treatment for patients with
PIK3CA mutations and also have potential benefits for
patients with PIK3CA wild-type tumors.
Conclusions
Our results show that the gain of function conferred by
PIK3CA mutations contributes to resistance to HER2 in-
hibitors by partially uncoupling PI3K signaling from
HER2 inhibition. They also show that, though maximal
HER2 blockade is insufficient to overcome the effects of
the mutation, addition of a PI3K inhibitor to HER2 inhibi-
tors can reverse or prevent resistance. This suggests that
this combination may be an effective strategy to overcome
resistance in patients that warrants clinical testing.
Additional files
Additional file 1: Table S1. The breast cancer SNaPshot screen queries
18 point mutations in 3 genes.
Additional file 2: Table S2. Breast cancer SNaPshot screen multiplex
polymerase chain reaction primers.
Additional file 3: Table S3. Single-base extension primers for the
breast cancer SNaPshot screen.
Additional file 4: Table S4. Breast SNaPshot screen spiking primers
used for pan-positive control assay.
Additional file 5: Figure S1. Expression of ectopic PIK3CA constructs.
Lysates from parental cells or cells infected with wild-type, E545K (EK) or
H1047R (HR) PIK3CA retroviral constructs were analyzed by immunoblot-
ting with the indicated antibodies. The PIK3CA constructs contain a
C-terminal hemagglutinin (HA)-tag.
Additional file 6: Figure S2. Phosphoinositide 3-kinase (PI3K) mutation
shifts the half-maximal inhibitory concentration for lapatinib inhibition of
PI3K signaling. Cells expressing wild-type or mutant PI3K constructs were
treated with a range of lapatinib concentrations (0.0016 to 5 μM) and
pHER2, pAkt and pS6 measured by enzyme-linked immunosorbent assay.
Results were normalized to untreated cells and inhibitor response curves
were fitted with GraphPad from a mean of three experiments (bars = SEM).
Additional file 7: Figure S3. Acquired E542K mutation in BT474
lapatinib resistant cells shifts the lapatinib half-maximal inhibitory
concentration (IC50) for phosphoinositide 3-kinase signaling. BT474
parental or lapatinib-resistant cells cultured without lapatinib for at least
2 weeks were treated with a range of lapatinib doses and analyzed by
enzyme-linked immunosorbent assay for pHER2, pAkt and pS6. The
inhibitor response curves and mean IC50 values from three separate
experiments are displayed (bars = SEM).
Additional file 8: Figure S4. Cell lines with endogenous
phosphoinositide 3-kinase (PI3K) mutations show uncoupling of PI3K
signaling from HER2 inhibition by lapatinib. (A) Cell lines (wild-type or
with PI3K mutations as indicated) were treated with a range of lapatinib
doses and analyzed by enzyme-linked immunosorbent assay for pHER2,
pAkt and pS6. The inhibitor response curves derived from a mean of
three separate experiments are shown. (B) The level of pS6 remaining
at the 5 μM lapatinib dose, normalized to untreated cells, is shown
(mean ± SEM).
Additional file 9: Figure S5. Lapatinib-resistant cells utilize H1047R
mutant PIK3CA for phosphoinositide 3-kinase (PI3K) signaling. Cells in-
fected with E545K or H1047R mutant PIK3CA vectors were selected for
lapatinib resistance. PI3K was immunoprecipitated from cells before and
after selection for resistance, and the level of hemagglutinin (HA) expres-
sion was determined by immunoblot analysis of the immune complexes.
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antibodies and LI-COR software. The relative intensity of HA expression in
resistant cells compared with their unselected counterparts is shown.
The mean value (±SEM) of five or six replicate immunoprecipitations is
displayed.
Additional file 10: Figure S6. Phosphoinositide 3-kinase (PI3K) muta-
tion allows for emergence of resistant colonies, even to dual HER2
blockade. Cells expressing wild-type or PI3K mutations as indicated were
seeded into 12-well plates and were treated with lapatinib, trastuzumab
or a combination of the two 24 hours after plating as indicated. Cells
were grown for 2 to 3 weeks in media, and drugs were replenished twice
weekly. At the end of treatment, the cells were fixed and stained with
crystal violet.
Additional file 11: Figure S7. BKM120 is required to maximally inhibit
phosphoinositide 3-kinase signaling in tumor xenografts. Tumors from
BT474 cells that remained after 28 days of treatment with BKM120 (B),
lapatinib (L) or trastuzumab (T) in the combinations indicated were
harvested, and lysates were prepared and analyzed by immunoblotting
with the indicated antibodies.
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